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Abstract
Oxidative damage occurs in multiple sclerosis, but is difficult to identify ante-
mortem and remains an unknown contributor to disease progression. Carbony-
lation is a quantitative measure of protein oxidation. Cerebrospinal fluid
samples from multiple sclerosis patients showed elevated carbonylated protein
levels compared to controls. In experimental autoimmune encephalomyelitis,
carbonylated protein levels in cerebrospinal fluid correlated tightly with those
found in inflamed spinal cord tissues. Furthermore, concentrations in cere-
brospinal fluid and spinal cord responded in parallel to an antioxidant inter-
vention that also attenuated disease symptoms. These data suggest that
carbonylated cerebrospinal fluid proteins could be a quantitative, sensitive, and
disease-relevant biomarker in multiple sclerosis.
Introduction
Oxidative damage occurs in both the gray and white matter
of multiple sclerosis (MS) patients.1–8 Tissue myeloid cells,
both infiltrating monocytes and resident microglia, gener-
ate reactive oxygen species (ROS) in this disease setting,1–3
and confirmed central nervous system (CNS) targets of
oxidation include the lipids, nucleic acids, and proteins of
both glia and neurons.1–8 While such oxidative changes
generally increase with disease duration and clinical mea-
sures of disability,1–8 a convenient way to measure them
within the CNS of living patients has remained elusive.
This greatly hampers investigation of potential antioxidant
interventions, particularly among patients with secondary-
progressive MS (SPMS) where oxidative damage is most
apparent and where approved therapies are lacking.
While ROS are short-lived molecules, the proteins they
modify are more stable and are amenable to measurement
as a surrogate of oxidative injury. Carbonylation is the
most frequent form of irreversible protein oxidation, and
carbonylated proteins are easily quantified in biological
samples.9 Proteins modified in this manner are well
known to accumulate in the brains of MS patients.4 Still,
only a handful of studies have measured carbonylated
proteins in human cerebrospinal fluid (CSF),10,11 and only
one suggests that these proteins might serve as a biomar-
ker of oxidative injury within the CNS.11 This study inves-
tigated this question using samples from humans with MS
and mice with experimental autoimmune encephalomyeli-
tis (EAE). The data show that carbonylated proteins accu-
mulate in the CSF of MS patients compared to controls,
and that levels correlate directly with both disease dura-
tion and expanded disability status scale (EDSS) scores. In
EAE, CSF carbonylated protein levels correlate closely with
those measured directly in inflamed spinal cord tissues,
and both CSF and tissue levels respond in parallel to an
intervention that inhibits CNS ROS production and atten-
uates disease symptoms. Together, these findings suggest
that quantification of carbonylated proteins in CSF could
be a convenient biomarker of ongoing oxidative injury in
the CNS of SPMS patients.
Materials and Methods
Human CSF samples
All CSF samples were obtained from patients who had a
lumbar puncture for clinical purposes. Collection of an
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additional specimen for research use was done so with
written informed consent. The Institutional Review Board
of the University of Michigan Medical School approved
the acquisition and storage of these samples
(HUM00066792). Specimens were collected on ice, cen-
trifuged at 2000g to remove cellular contents, and stored
at 80°C until use.
Animals
Female C57BL/6 mice (8–10 weeks old) were purchased
from Harlan Laboratories (Indianapolis, IN). The Univer-
sity of Michigan Committee on the Use and Care of Ani-
mals approved all the procedures herein (PRO00006745),
and experiments were conducted in accordance with the
United States Public Health Service’s Policy on Humane
Care and Use of Laboratory Animals. Subcutaneous
immunization of mice with 100 lg of myelin oligoden-
drocyte glycoprotein (MOG)35-55 peptide (Biosynthesis,
Lewisville, TX) emulsified in complete Freund’s adjuvant
(Difco, Detroit, MI) containing an additional 4 mg/mL
heat killed Mycobacterium tuberculosis, H37Ra (Difco)
induced EAE. All mice also received 300 ng of pertussis
toxin (List Biological Laboratories, Campbell, CA) via
intraperitoneal (i.p.) injection on the day of immuniza-
tion and 48 h later. Animals were then given 25 mg/kg of
telmisartan (Sigma-Aldrich, St. Louis, MO) or a vehicle
control twice daily via i.p. injection in 200 lL of 0.9%
sodium chloride solution, pH 9.0, beginning on day 10.
Thereafter, each animal was scored daily for clinical signs
of EAE using the following scale: 0 = no signs of disease;
1 = flaccid tail or hind limb weakness; 2 = flaccid tail,
hind limb weakness, and loss of righting reflex; 3 = par-
tial hind limb paralysis; 4 = complete hind limb paralysis;
5 = moribund or dead. At day 20 postimmunization,
some mice were killed and CSF collected using a pulled
glass capillary pipette via cisternal puncture. Animals then
underwent transcardiac perfusion with chilled phosphate-
buffered saline, and spinal cords were dissected for bio-
chemical analyses.
Measurement of carbonyl groups
Lumbar spinal cords were homogenized in 10 mmol/L
EDTA, pH 7.5, and kept at 80°C until use. Samples
were treated with 1% streptomycin sulfate in 50 mmol/L
potassium phosphate buffer, pH 7.2, for 15 min and cen-
trifuged at 6000g to remove nucleic acids. The protein
content of each sample was measured using the Pierce
Coomassie Protein Assay Reagent (Thermo Fisher Scien-
tific, Rockford, IL) and adjusted to 1 mg/mL. Protein car-
bonylation was measured in each experimental sample
using the Protein Carbonyl Colorimetric Assay Kit
(Cayman Chemical, Ann Arbor, MI). Two hundred
microliters of each mouse spinal cord homogenate and
human CSF sample, and 5 lL of each mouse CSF sample,
were incubated with 800 lL of 2,4-dinitrophenylhydrazine
in 2.5 mol/L HCl for 1 h at room temperature. Controls
for each specimen were treated with 2.5 mol/L HCl alone.
Samples were sequentially precipitated with 20% trichlor-
oacetic acid (TCA), 10% TCA, and a 1:1 mixture of etha-
nol/ethyl acetate. Pellets were suspended in guanidine
hydrochloride and the absorbance of each sample and its
respective control read at 360 nm. A portion of each sam-
ple was retained to remeasure its total protein content as
described above. The amount of carbonyl groups present
in each sample was calculated using a molar extinction
coefficient of 22,000 cm1, its total protein concentration,
and its corrected absorbance (sample minus control).
Measurement of tissue superoxide-
generating activity
The capacity of each mouse spinal cord to generate ROS
was measured directly ex vivo using the well-established
cytochrome c reduction assay, as described.12 Results are
presented as nmol O2
- produced/mg tissue protein.
Statistical comparisons
The Prism 6.0 software package (GraphPad Software, La
Jolla, CA) was used for all statistical analyses. Student’s
t-tests were applied when comparing a single parameter
under two experimental conditions, a one-way analysis of
variance (ANOVA) with a post hoc Bonferroni’s multiple
comparison test was used to investigate the significance of
a single parameter’s change across multiple groups, while
a two-way ANOVA with a post hoc Bonferroni’s multiple
comparison test was used to compare experimental find-
ings between two groups over time. Correlations were
determined using Spearman nonparametric tests and two-
tailed P-values. In all cases, differences at a P < 0.05 level
were considered significant.
Results
Carbonylated proteins accumulate directly in the brains
of patients with SPMS,4 and proteins modified in this
way are considered both a sensitive and reliable indicator
of ongoing ROS-mediated tissue damage.13 Levels of car-
bonylated proteins were measured in CSF samples
obtained from MS patients (n = 73) and noninflamma-
tory neurologic disease (NIND) controls (n = 17). Mean
concentrations were elevated across the spectrum of MS
subtypes, rising steadily from patients with clinically iso-
lated syndromes (CIS) through relapsing-remitting disease
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and into SPMS (Fig. 1A). Primary progressive MS was
not assessed due to a lack of available samples. Among
the 73 MS samples, CSF carbonylated protein concentra-
tions correlated directly with both disease duration and
EDSS score, but not with age (Fig. 1B–D).
The angiotensin receptor blocking (ARB) drug, telmis-
artan, was recently shown to be neuroprotective in mice
with lethal viral encephalitis by exerting antioxidant activ-
ity directly within the CNS.12 To determine whether this
same intervention could modulate CNS protein carbony-
lation during autoimmune demyelination, mice with
active EAE were treated twice daily with telmisartan start-
ing just prior to symptom onset. Similar to what has been
reported with other ARBs in EAE,14–16 this regimen sup-
pressed clinical disease severity (Fig. 2A). Furthermore,
10 days of drug administration also inhibited ROS pro-
duction directly in the spinal cord (Fig. 2B), and it
significantly reduced levels of carbonylated moieties pre-
sent in both the spinal cord (Fig. 2C) and CSF compart-
ments (Fig. 2D). A remarkable correlation was observed
between levels of carbonyl groups in CSF and spinal cord
among individual animals (Fig. 2E).
Discussion
Recent microscopic studies of SPMS tissues have fostered
a growing consensus that processes driving this phase of
disease must account for a relative shift away from focal
areas of inflammatory demyelination and toward ones
causing more widespread degeneration of chronically
demyelinated axons, cortical demyelination, and global
CNS tissue volume loss. These shared pathologic features
are poorly reproduced in current animal models, and the
lack of a validated experimental system has clouded
Figure 1. Carbonylated proteins are increased in the CSF of patients with MS compared to non-MS controls, and levels in MS patients correlate
directly with disease duration and disability scores. (A) Protein carbonyls were quantified in CSF samples collected from patients with various
noninflammatory neurologic diseases (NIND, n = 17), clinically isolated syndromes (CIS, n = 23), relapsing-remitting MS (RRMS, n = 39) or
secondary-progressive MS (SPMS, n = 11). Mean concentrations in each group were significantly different from one another (P < 0.0001). (B–D)
When CIS, RRMS, and SPMS patient samples were grouped together (n = 73), CSF carbonylated protein levels correlated directly with disease
duration and EDSS score, but not with age. Correlation coefficients (r) and two-tailed P -values are shown. CSF, Cerebrospinal fluid; MS, multiple
sclerosis; EDSS, expanded disability status scale.
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Figure 2. Systemic administration of telmisartan suppresses clinical disease severity, tissue ROS production, and protein carbonylation in the
central nervous system of mice with EAE. (A) Mice with active immunization EAE were treated twice daily with telmisartan (n = 10) or a vehicle
control (n = 10) beginning 10 days following disease induction (arrow). Clinical disease scores were significantly different between the two
groups (P < 0.0001). (B) Telmisartan potently suppressed EAE-induced tissue ROS production compared to mice given a vehicle control
(P = 0.0022). (C, D) Telmisartan simultaneously inhibited the formation of carbonylated moieties directly in spinal cord tissue (P = 0.0018) and
CSF (P = 0.0005) compared to a vehicle control. (E) Levels of carbonylated moieties in CSF and spinal cord were tightly correlated with each other
in individual animals (P < 0.0001). CSF, cerebrospinal fluid.
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investigation of disease mechanisms and impeded the
development of therapies to slow SPMS progression. Clin-
ical and radiological heterogeneity is another obstacle that
has hampered the development of treatments for this dis-
order. Indeed, without both good mechanistic targets and
validated study endpoints, clinical trials in SPMS have
lagged far behind the remarkable progress made for
patients with relapsing-remitting disease. A quantitative,
reliable, and disease-relevant biomarker for SPMS is
sorely needed.
Oxidative damage is found in MS tissues at
autopsy,1–8 but this process escapes detection using con-
ventional laboratory and CNS imaging techniques. It also
remains unproven as a pathogenic mechanism that actu-
ally drives MS progression. The data presented here
show that increased carbonylation of CSF proteins is a
consistent finding in MS patients, and that proteins
modified in this way progressively accrue as the disease
course lengthens and disability accumulates, and not
simply as patients get older. Furthermore, CSF protein
carbonylation accurately reflects oxidative events occur-
ring within the inflamed spinal cords of mice with EAE.
This suggests either tissue ROS can reach the CSF
directly, or there is a dynamic exchange of these modi-
fied proteins between the CNS parenchyma and the CSF
compartment. The fact that protein carbonyl levels
respond to an intervention that both reduces tissue ROS
production and attenuates disease symptoms demon-
strates that a shift between their production and removal
can be accomplished in EAE. Reduced proteosomal
degradation contributes to the accumulation of tissue
carbonylated proteins during chronic EAE,17 but these
protein modifications also clearly happen faster in dis-
eased versus control mice.
Because CSF proteins rapidly efflux from the CNS via
macrovesicular transport across arachnoid granulations,18
elevated protein carbonyl content in this compartment
must reflect an active, ongoing protein oxidation process.
This raises some hope that antioxidant approaches could
become a viable therapeutic strategy in SPMS. Having a
convenient tool to quantify such biochemical events
within the CNS should greatly accelerate the drug discov-
ery process.
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